Trial Type: Esophageal Cancer

LS-P-HAT

A Phase 1 Study of NM32-2668 (Anti ROR1/Anti CD3/Anti-HSA Tri-Specific Antibody) in Adult Patients with Selected Advanced Solid Tumors

Status: Open

Trial Type: Breast Cancer, Early Phase Trials for Multiple Cancer Types, Esophageal Cancer, Gastric Cancer, Kidney and Bladder Cancer, Lung Cancer, Melanoma and Skin Cancers, Ovarian Cancer, Soft Tissue and Bone Cancer, Uterine Cancer

Contact: Benedito Carneiro, MD

Benedito.carneiro@brownhealth.org

GPC3CD3 Trial

A phase 1/2 study of SAR444200, an anti-GPC3/CD3 bispecific antibody in patients with advanced solid tumors

Status: Open

Trial Type: Colon Cancer, Esophageal Cancer, Liver and Bile Duct Cancer

Contact: Khaldoun Almhanna, MD

kalmhanna@brownhealth.org

Port Trial – AZD0901

(Port trial): Anti claudin antibody drug conjugate AZD0901 for solid tumors expressing claudin 18.2

Status: Open

Trial Type: Esophageal Cancer

Contact: Alex Raufi, MD

araufi2@brownhealth.org

LS-P-TIDE

inhibitor of MTAP for patients with MTAP gene alterations in gastric esophageal, NSCLC and bladder cancer

Status: Open

Trial Type: Early Phase Trials for Multiple Cancer Types, Esophageal Cancer, Gastric Cancer, Kidney and Bladder Cancer, Lung Cancer

Contact: Benedito Carneiro, MD

Benedito.carneiro@brownhealth.org

BrUOG 413

Adjuvant Trastuzumab Deruxtecan (Enhertu) + Nivolumab For Patients Who Are Disease Free After Completion of Trimodality Treatment For HER-2expressing Esophagogastric cancer.

Status: Open

Trial Type: Esophageal Cancer

Contact: Howard Safran, MD

hsafran@brownhealth.org